Label: XELRIA FE- norethindrone and ethinyl estradiol and ferrous fumarate kit

  • NDC Code(s): 70700-308-84, 70700-308-85
  • Packager: Xiromed LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated October 20, 2024

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use XELRIA FE safely and effectively. See full prescribing information for XELRIA FE. XELRIATM FE (norethindrone and ethinyl estradiol ...
  • Table of Contents
    Table of Contents
  • BOXED WARNING (What is this?)

    WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS

    Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke [see Contraindications (4)]

    Close
  • 1 INDICATIONS AND USAGE
    Xelria Fe is indicated for use by females of reproductive potential to prevent pregnancy.
  • 2 DOSAGE AND ADMINISTRATION
    2.1 How to Start Xelria Fe - Xelria Fe is dispensed in a blister pack [see How Supplied/Storage and Handling (16)]. Xelria Fe may be started using either a Day 1 start or a Sunday start (see ...
  • 3 DOSAGE FORMS AND STRENGTHS
    Xelria Fe is available in cartons of 3 blister packs. Each blister pack contains 28 tablets in the following order: 21 yellow, round, uncoated flat (active) tablets debossed with “226” on one ...
  • 4 CONTRAINDICATIONS
    Xelria Fe is contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic diseases. Examples include women who are known ...
  • 5 WARNINGS AND PRECAUTIONS
    5.1 Thrombotic Disorders and Other Vascular Problems - Stop norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets (chewable) if an arterial thrombotic event or ...
  • 6 ADVERSE REACTIONS
    The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling: Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions ...
  • 7 DRUG INTERACTIONS
    Consult the labeling of concurrently used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations. 7.1 Effects of Other Drugs ...
  • 8 USE IN SPECIFIC POPULATIONS
    8.1 Pregnancy - There is little or no increased risk of birth defects in women who inadvertently use COCs during early pregnancy. Epidemiologic studies and meta-analyses have not found an ...
  • 10 OVERDOSAGE
    There have been no reports of serious ill effects from overdosage of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.
  • 11 DESCRIPTION
    Xelria Fe is a combinational contraceptive containing the progestational compound norethindrone and the estrogenic compound ethinyl estradiol. The packaging includes 21 yellow tablets composed of ...
  • 12 CLINICAL PHARMACOLOGY
    12.1 Mechanism of Action - COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm ...
  • 13 NONCLINICAL TOXICOLOGY
    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility - [See Warnings and Precautions (5.11) and Use in Specific Populations (8.1).]
  • 14 CLINICAL STUDIES
    The data presented in Section 14 are from a clinical trial conducted with norethindrone 0.4 mg/ethinyl estradiol 0.035 mg tablets. Norethindrone and ethinyl estradiol tablets (chewable) and ...
  • 16 HOW SUPPLIED/STORAGE AND HANDLING
    16.1 How Supplied - Xelria Fe is available in cartons of 3 blister packs: NDC 70700-308-85 - Each blister pack contains 28 tablets in the following order: 21 yellow, round, uncoated flat ...
  • 17 PATIENT COUNSELING INFORMATION
    See FDA-Approved Patient Labeling (Patient Information and Instructions for Use) Counsel patients about the following information: Cigarette smoking increases the risk of serious cardiovascular ...
  • PATIENT INFORMATION
    Xelria Fe (Norethindrone and Ethinyl Estradiol Tablets, USP (Chewable) and Ferrous Fumarate Tablets (Chewable)) What is the most important information I should know about Xelria Fe? Do not ...
  • PRINCIPAL DISPLAY PANEL - 0.4 mg /0.035 mg
    NDC 70700-308-85 - Rx only - Xelria Fe (Norethindrone and Ethinyl Estradiol Tablets USP (Chewable) andFerrous Fumarate Tablets (Chewable))* 0.4 mg /0.035 mg - 3 pouches, each pouch contains one ...
  • INGREDIENTS AND APPEARANCE
    Product Information